HKG:1177

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
·····

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus

GSK has signed an exclusive deal with Sino Biopharmaceutical’s CTTQ unit to launch hepatitis B drug candidate bepirovirsen in China, gaining access to over 5,000 medical centres. CTTQ will handle importation, distribution, and promotion, while GSK retains regulatory control. Bepirovirsen is not yet approved anywhere. Financial terms were not disclosed.
May 13, 2026

Stock Market Today

  • Temple & Webster (ASX:TPW) Shares Fall 75%: Is It a Buy Amidst Market Challenges?
    May 26, 2026, 7:58 PM EDT. Temple & Webster Group Ltd (ASX:TPW) shares have plunged roughly 75% over 12 months due to slowed housing demand, rising costs, and consumer tightening. Despite a recent 19.8% revenue rise, profits tumbled 36%, and gross margins slipped from 32.4% to 30.5%, impacted by high customer acquisition costs and expansion efforts. The company's post-earnings 25% share drop highlights investor concerns. However, a May 2026 trading update showed improved profitability after strategic adjustments. Incoming CEO Susie Sugden's marketing expertise may steer growth amid ongoing challenges. Temple & Webster remains a speculative buy for patient investors seeking long-term gains from the growing Australian furniture market, despite near-term volatility.